CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer

Yuchen Li1,*, Yinfeng Gu1,*, Pengyue Yang1, Yan Wang1, Xibao Yu1, Yangqiu Li1, Zhenyi Jin1,2, Ling Xu1,3

1Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, People’s Republic of China; 2Department of Pathology, School of Medicine, Jinan University, Guangzhou, 510632, People’s Republic of China; 3Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, 510632, People’s Republic of China

*These authors contributed equally to this work

Abstract: Immunotherapy utilizing T cells that attack tumors is a promising strategy for treatment, but immune suppressive T cell subsets, such as regulatory T cell (Treg), and immune checkpoint molecules, including programmed death-1 (PD-1), can suppress the intensity of a T cell immune reaction and thereby impair tumor clearance. Cluster of differentiation 69 (CD69), known as an early leukocyte activation marker, can be used as a measure or early marker of T cell activation. In recent years, the functions of CD69 in the regulation of Treg/Th17 (T helper cell 17) differentiation and in the tissue retention of T cells have attracted considerable interest. These functions are related to the role of CD69 in immune suppression in tumor environments (TME). In this review, we first summarized current perspectives in the biological function of CD69 and demonstrated that CD69 acts as a regulator of T cell activation, differentiation, retention, and exhaustion. Then, we discussed recent advances in understanding of CD69 deficiency and anti-CD69 antibody administration and shed light on the value of targeting on CD69 for cancer immunotherapy and prognosis prediction.

Keywords: CD69, T cell, immunotherapy

Introduction

In the past two decades, monoclonal antibody (mAb) immunotherapy, immune checkpoint blockade therapy, and chimeric antigen receptor T cell (CAR-T) therapy have changed the therapeutic landscape of tumor patients. Numerous molecules with immunoregulatory functions have been discovered, which can be applied to cancer immunotherapy.

CD69 is a recognized classical marker of white blood cell activation.1 It appears faster on the cytoplasmic membranes of activated cells than CD252 and is thus regarded as an early marker of lymphocyte activation. CD69 can be expressed in hematopoietic or immune cells and plays a regulatory role. It can promote tissue residency, regulate Th17/Treg cell differentiation, and contribute to the exhaustion of resident memory T cells, especially in the tumor microenvironment.

Based on the various roles of CD69 in immune function regulation, targeting CD69 in the treatment of immune diseases and tumors seems to be a theoretically feasible strategy. The practical outcome and effectiveness of this approach have been considered to be of equal importance. Previous studies have tended to focus on the roles of CD69 in inducing Treg differentiation. Given that numerous studies have revealed its involvement in tissue residency and tumor immunity, the immunoregulatory roles of CD69 need to be reassessed. In this review, we summarized the basic expression, transcription regulation, and ligands of CD69, further introduced the immunomodulatory function of CD69 in regulating the balance of Treg/Th17, the retention of tissue-resident memory T (T_RM) cells, and the exhaustion of T cells. In addition, we further reviewed the abnormal expression of CD69 in cancer and discussed the prognostic value and the possibility of targeting CD69 for cancer treatment, especially for cancer immunotherapy.
Expression of CD69 in Hematopoietic/Immune Cells

CD69 is a member of the differentiation antigen cluster previously called activation-inducing molecule (AIM), activation antigen (EA-1), leukocyte surface antigen (Leu-23), or MLR-3 antigen. Discovered in 1981, CD69 is a disulfide-linked homodimer protein with two differentially glycosylated subunits (28–32 kDa). Each subunit consists of an extracellular C-type lectin domain connected to a single-spanning transmembrane region followed by a short cytoplasmic tail. CD69 is broadly expressed on the surfaces of most hematopoietic lineages, including activated T and B lymphocytes, natural killer (NK) cells, murine macrophages, neutrophils, and eosinophils, and constitutively expressed on human monocytes, platelets, epidermal Langerhans cells, and bone-marrow myeloid precursors. However, the expression of CD69 cannot be detected in unstimulated peripheral blood leukocytes and activated monocytes. Recently, CD69 was found to be constitutively expressed in resident CD8+CD4−, Treg, γδ T cells, innate lymphocytes, natural killer T cells in all the tissues explored, and skin dendritic cells (DCs). The expression of CD69 can lead to the internalization and degradation of sphingosine 1-phosphate receptor 1 (S1P1), which plays a role in cell egress from lymphoid tissues and enters the blood by binding with sphingosine-1-phosphate (S1P).

Transcriptional Regulation of CD69 Expression

The CD69 gene is located on mouse chromosome 6 and human chromosome 12. This complex includes a variety of genes encoding C-type lectins, which play important roles in the immune system. The CD69 proximal promoter contains the canonical TATA box and binding sites for early-response inducible transcription factors, such as NF-κB, AP1, Erg-1, Erg-3, and ATF-3/CREB. Relative to the promoter, the 5′ region of CD69 contains four conserved noncoding sequences 1 to 4 (CNS1–4). These elements display DNase hypersensitivity and bear regulatory cell-type-specific histone marks that undergo changes during development and activation. CNS2 is the most intensively studied element. It is located 4 kb upstream of the human CD69 transcription start site, which is occupied by dense clusters of transcription factors, such as Oct1 and RUNX1, and it displays promoter and enhancer functions. As demonstrated by Jennifer et al, CNS2 is necessary not only to activate CD69 expression upon induction but also to sustain basal activity. This kind of basal activity may contribute to the sustained expression of CD69 in tissue-resident memory T cells (T RM). As more immune regulation function of CD69 were found, the basic regulation mechanism of CD69 gene expression in different kind of immune cells needs further investigation.

Ligands of CD69

The functions of CD69 can be better understood by studying its ligands. To date, CD69 has four potential ligands: galactolectin-1 (Gal-1), calprotectin (S100A8/S100A9 complex), myosin light chains 9, 12a, and 12b (Myl9/12), and oxidized low-density lipoprotein (ox-LDL). Gal-1 is a β-galactoside-binding protein that can be expressed in macrophages and DCs and plays an important role in the regulation of adaptive immune responses by altering the fate and phenotypes of Th cells. IL-10 is the main component of Gal-1 immunomodulatory characteristics, and Gal-1-induced IL-10+ T cells can effectively inhibit T cell proliferation and the T cell-mediated inflammatory response. The expression of CD69 by activated T cells triggers an anti-inflammatory mechanism mediated by Gal-1 that can promote the production of cytokines, such as transforming growth factor-β (TGF-β) and IL-35, regulating the immune response and preventing the pathogenic Th17 response. Thus, CD69 regulates the key functions of murine and human Th17 effector cells by interacting with Gal-1. The S100A8/S100A9 complex belongs to the S100 protein family and is a natural ligand for CD69 in human peripheral blood mononuclear cells. It is expressed and secreted by bone marrow (BM) cells and has proinflammatory and anti-inflammatory effects. Glycosylation-dependent interactions between CD69 and S100A8/S100A9 complexes are required for the secretion of TGF-β and IL-4 and the transformation of naïve CD4+ T cells to Treg cells. Therefore, Gal-1 and S100A8/S100A9 can regulate T cell differentiation by upregulating Treg differentiation and suppressing Th17 differentiation. MyI9 and MyI12 belong to the myosin light chain molecular family. MyI9 can be produced by platelets and form MyI9 nets during inflammation, and CD69-expressing antigen-primed T cells attached to MyI9 nets can be recruited to inflamed tissues and cause antigen-specific T cells to remain in inflamed tissues. Increased secretion of IL-33 and TNF-α leads to the deterioration of inflammation. This finding suggests that the binding of MyI9 to CD69 can be responsible for the recruitment of lymphocytes and the regulation of inflammation. In addition,
ox-LDL is a new ligand of CD69. CD69 can reduce the expression of IL-8 and IFN-γ in T cells by binding to oxLDL and internalizing the receptor. The CD69–oxLDL complex can promote the transcription of nuclear receptor subfamily 4 group A (NR4A) and further regulate the differentiation between Th17 and Treg, promoting affinity to Treg cells. In addition, the CD69–oxLDL complex can promote the activation of the nuclear factor of activated T cells (NFAT) in human T cells and further induce the expression of PD-1 and NR4A3, thereby negatively regulating the inflammatory response. The roles of CD69 can be mediated by different ligands. The binding of Gal-1, S100A8/S100A9 complexes, and ox-LDL to CD69 may be involved in the negative regulation of immune response, whereas the binding of Myl9/12 can lead to the positive development of inflammation. Overall, CD69 may play multiple roles in T cell-mediated immunoregulation by interacting with different ligands. The effects of the interaction of CD69 on T cells with the four ligands are depicted in Figure 1.

**CD69 Plays a Role in the Regulation of Treg/Th17 Differentiation**

T cell differentiation is primarily dependent on cytokines that stimulate the JAK/STAT signaling pathway, resulting in the expression of lineage-specific transcription factors and effector cytokines. Th17 and Treg cells represent two CD4+ T cell subsets that require TGF-β during their development but eventually differentiate into two different phenotypes with opposite activities. In contrast, TGF-β in the absence of IL-6 can activate STAT5, which can push cell differentiation away from Th17 and toward Treg cells. Conversely, TGF-β and IL-6 are required for Th17 differentiation, which is associated with the activation of STAT3 and retinoic acid-associated orphan receptor γt (RORγt). Therefore, Treg/Th17 differentiation is based on the STAT3/STAT5 balance.

![Figure 1](https://doi.org/10.2147/ITT.S439969)
CD69 can participate in Treg/Th17 differentiation by controlling the STAT3/STAT5 balance (Figure 2A). The cytoplasmic tail of CD69 is associated with the JAK3/STAT5 signaling pathway, and CD69 can inhibit JAK2/STAT3 signaling and thereby negatively regulate the transcription of RORγt and inhibit the differentiation of cells into the Th17 lineage. Additionally, CD69 can enhance the phosphorylation of the JAK3/STAT5 signaling pathway and promote Treg differentiation, and the addition of exogenous IL-2 to CD69-deficient cells restores STAT5 phosphorylation and inhibits Th17 differentiation. CD69 deficiency significantly enhances the inflammatory response in the asthmatic models of antigen-induced airway allergy and increases the Th17 response. Thus, CD69 can promote the differentiation of T cells to Tregs while inhibiting the differentiation toward Th17 cells and regulating T cell-mediated immunity.

In addition to STAT3/STAT5, numerous transcription factors are involved in Treg/Th17 differentiation. Heat shock transcription factor 1 (HSF1) deficiency or inhibition impairs CD69+ Treg generation and colitis repression, highlighting that HSF1 can promote CD69 transcription and CD69+ Treg differentiation. NR4A is an important factor controlling Th17/Treg differentiation, and ox-LDL-CD69 enhances the expression of the transcription factor NR4A, especially NR4A3 and NR4A1, thereby promoting Treg cell differentiation. Hypoxia-inducible factor-1α (HIF-1α) promotes Th17 differentiation while inhibiting Treg and is related to CD69 regulation in T cell differentiation (Figure 2A). The S1P1–mammalian target of rapamycin (mTOR)–HIF-1α axes is required for Th17/Th1 differentiation. Therefore, Treg generation induced by a pathway involving HIF-1α may be promoted by CD69, which according to suppresses S1P1 activity. Notably, CD69 establishes lateral interactions with LAT1–CD98, which could activate the HIF-1α in the downstream mTOR signaling pathway thus leading to the Th17/Th1 development and prevents Treg differentiation. CD69 can inhibit S1P1 activity while increasing LAT1–CD98, leading to different results in Treg/Th17 differentiation. Therefore, it can be speculated that CD69 plays distinct roles.

Figure 2 CD69 participates in the balance in Treg/Th17 differentiation. (A) oxLDL binding to CD69 promotes Treg differentiation by enhancing NR4A (NR4A1 and NR4A3) expression (Left). Binding of S1P to its receptor S1P1R promotes the activation of the mTOR/HIF-1α and JAK2/pSTAT3 pathways, thereby promoting Th17 differentiation. CD69 can promote the internalization and degradation of S1P1R and activate the JAK/pSTAT5 pathway, thereby blocking S1P1R signaling and promoting Treg differentiation (Right). (B) The combination of CD69 and CD98-LAT1 complex can increase Trp/Leu uptake, amino acid uptake can promote the activation of the mTORC signaling pathway and thereby promote Treg differentiation. Endogenous tryptophan photo-product, FICZ, which combined with AHR and promoted its nuclear entry, attenuated the inhibition of HIF-α by intracellular AHR, further promoted Th17 differentiation, and inhibited Treg differentiation.
under different conditions. Overall, CD69 plays a role in the regulation of Treg/Th17 differentiation apart from acting as an activation marker. The crucial role of CD69 in immunosuppression is promoting CD69+ Treg differentiation. Undoubtedly, CD69 has become an important part of ongoing basic and clinical research into various kinds of inflammatory diseases. The mechanisms of CD69 in regulating Treg/Th17 balance are shown in Figure 2.

**Expression of CD69 in T<sub>RM</sub> Cells**

T<sub>RM</sub> cells constitute the heterogeneous populations of T cells with effector and memory T cell functions and express resident gene signatures that allow them to transport, reside, and patrol peripheral tissues and respond quickly to red flags for long-term effective immune protective effects. CD69 expression can be detected in most identified T<sub>RM</sub> cells, regardless of cellular origin (embryonic or BM circulating cells) and the presence or absence of antigens, suggesting that tissue-specific environmental cues may promote the retention or survival of tissue-resident immune cells by controlling CD69 expression. Notably, CD69<sup>−</sup> cells can be functionally present in the vascular compartments of the kidneys and liver, indicating that some T cells without CD69 also show tissue residency. Numerous phenotypes can be detected on T<sub>RM</sub> cells, including CD103, CD49a, and CD44, and can vary among tissue-derived T<sub>RM</sub> cells because of variations in tissue compartments. Inhibitory markers, such as PD-1 and CD101, are expressed on T<sub>RM</sub> surfaces, but whether their expression correlates with weak cytotoxicity and T cell exhaustion remains unclear. Reduced expression of receptors controlling the T cell egress, including CCR7, CD62L, and S1P1, contributes to the tissue residence of T<sub>RM</sub> cells. Thomas et al showed that CD69 expression by mucosal memory T cells is a feature of localization in tissues and is not age dependent; even at birth, memory T cells in all tissues express this core phenotypic marker that distinguishes them from memory T cells in blood.

The S1P–S1P1 system controls the entry of T cells into lymphatic vessels. The S1P level is higher in blood than in intracellular or interstitial fluids, creating a steep S1P gradient that can facilitate the egress of lymphocytes from lymphoid organs, and the blockage of the S1P–S1P1 system results in a decrease in circulating lymphocytes. Similarly, a decreased S1P–S1P1 system is required for the tissue-resident ability of T<sub>RM</sub> cells. The transcriptional downregulation of S1P1 is required for the establishment of T<sub>RM</sub> cells, and this effect is induced by low Kruppel-like factor 2 (KLF2) expression. CD69 is associated with inhibition of S1P1 activity. This effect can be achieved by CD69, which enhances downstream IFN-α/β and decreases S1P1 activity. CD69 may form a complex with S1P1, leading to a conformational change in S1P1 and thereby facilitating its internalization and degradation. Low KLF2 transcription levels seem to correlate with CD69 expression in specific tissues and induce the tissue residency of T cells. These findings indicate the pivotal role of CD69 in T<sub>RM</sub> formation. CD69 negatively modulates S1P1 activity, thus leading to tissue residency. Given that KLF2 controls the transcription of S1P1 and CD62L, whether CD69 controls the expression of CD62L or other molecules related to T cell egress and the detailed mechanism by which CD69 induces tissue residency require further elucidation.

HIF-1α has also been proven to promote T<sub>RM</sub> differentiation. The number of CD69<sup>−</sup>CD103<sup>+</sup> cells showed a dose-dependent increase after treatment with the prolyl hydroxylase inhibitor FG-4592 (Roxadustat), given that HIF-1α can be hydroxylated by this enzyme. CD69 is a direct HIF-1α target gene responsible for hypoxia in tumor-infiltrating T lymphocytes (TILs). Thus, HIF-1α may participate in T<sub>RM</sub> formation by upregulating the CD69 expression, which may lead to T<sub>RM</sub> accumulation in the TME.

CD69 is a core marker of memory T cells in multiple tissue compartments. The role of CD69 in T<sub>RM</sub> formation remains unclear but may partially correlate with the transcription factors KLF2 and HIF-1α.

**CD69 Expression on TILs is Associated with T Cell Exhaustion**

In chronic infections with persistent antigen stimulation and in TMEs, CD8<sup>+</sup> T cells are often in a special state: T cell exhaustion or dysfunction. The stratification loss of effector function and proliferation and significant transcription and metabolic changes are the distinguishing features of T cells in an exhausted state. The main marker of T cell exhaustion is the upregulation of PD-1, and other inhibitory receptors, such as cytotoxic T lymphocyte antigen-4 and T cell immunoglobulin and ITIM domains (TIGIT). The PD-1/PD-L1 axis is important for T cell dysfunction because it blocks PD-1 or its ligand, PD-L1, which restores T cell function. The transient expression of PD-1 is a characteristic of normal T cell activation, and sustained exposure to antigens induces the sustained expression of PD-1, which may drive T cell exhaustion.

---

**ImmunoTargets and Therapy**

2024:13

https://doi.org/10.2147/ITT.S439969

DovePress
Research has demonstrated that CD69 expressed on TILs correlates with T cell exhaustion. In 2021, a study performed a transcriptomic analysis and found enhanced CD69 gene expression in pre-exhausted and exhausted CD8+ T cells isolated from colorectal cancer, hepatocellular carcinoma (HCC), and non-small cell lung cancer.\(^5\) Another study explored the process of T cell exhaustion in an animal chronic lymphocytic choriomeningitis virus infection model and found that Ly108 (Slamf6) and CD69 define a four-stage developmental trajectory of exhausted T cell subsets. One subset of terminally exhausted T cells hallmarked by Ly108−CD69\(^+\) exhibited poor division, limited persistence, and restrained developmental plasticity, and had high PD-1 and Thymocyte Selection Associated High Mobility Group Box (TOX) expression levels and apoptotic rates, while with low TCF1 expression levels. Another subset hallmarked by Ly108+CD69\(^+\) represents the progenitor of the other three exhaustion subsets including the terminal exhausted Ly108−CD69\(^+\) subset, which shows quiescent and resident features. Moreover, TILs with such phenotypes were also detected in human melanoma.\(^5\) In our previous work, we found an increased number of CD8+CD69+ T\(_{EM}\) cells in the BM of patients with de novo chronic myeloid leukemia, and a higher percentage of those cells express PD-1 and TIGIT when compared with healthy individuals.\(^5\) Recently, similar results were also detected in our acute myeloid leukemia cohorts (Unpublished data). These pieces of evidence indicate that CD69 expression on TILs is associated with T cell exhaustion. Furthermore, a study found that tumor progression is attenuated in CD69-deficient mice bearing 4T1-luc2 tumor cells, and the antitumor cytokine production of TILs was enhanced with decreased levels of exhaustion.\(^5\) The cytotoxicity of TILs is enhanced after targeting CD69, further revealing the possibility of T cell exhaustion induced by CD69.\(^5\),\(^5\),\(^5\)

Despite the unclear underlying mechanism by which CD69 expression contributes to T cell exhaustion, possible CD69\(^+\) T cell exhaustion may be explained by the CD69−SIP1 complex formation. The negative regulation of SIP1 by CD69 is required for the tissue residence of T cells, which may expose the T cells to a persistent antigen encounter environment, which is one of the main causative agents in T cell dysfunction.\(^5\),\(^5\),\(^5\) Besides, there was evidence showing that CD69 could promote PD-1 expression in CD4+ T cells through the activation of NFAT1 when engaged with oxLDL, which plays a role in the modulation of inflammation and vascular remodeling in cardiovascular diseases. Whether this mechanism also contributes to the exhaustion of TILs remains to be elucidated in the future.

Another notable problem is that CD69 positive T\(_{RM}\) cells are usually featured by expressing higher levels of a range of molecules commonly associated with terminally exhausted T cells (PD-1, CD39, and Tox) than other memory subsets, inversely, exhausted T cells could acquire tissue resident features of T\(_{RM}\) cells in order to adapt the tissue microenvironment, especially in the TME. Thus, in situations where the antigen burden is both high and unwavering, the extensive overlap between exhausted T cell and T\(_{RM}\) cell phenotypes may confute the classification of either subset.\(^6\),\(^6\) In summary, CD69 plays an important role in the formation of exhausted T cells, but how CD69 regulates the dynamic formation of exhausted T cells and the transformation of T\(_{RM}\) cells into exhausted cells or vice versa under different disease scenarios still needs to be further elucidated.

Expression of CD69 in Various Cancers as a Prognostic Marker

As CD69 has been recognized as one of the makers of T\(_{RM}\) cells, based on the gene expression of CD69 and CD4/CD8A, Shota Ida et al, identified T\(_{RM}\) cells correlate with the inflammatory tumor microenvironment and improved prognosis in head and neck squamous cell carcinoma.\(^6\) Bruni et al reported that the higher frequencies of CD69\(^+\) V\(\delta\)1 T cells in tissue sites and in peripheral blood are associated with slow liver metastatic progression and long overall survival in patients with colorectal cancer.\(^6\) Similarly, combined CD69\(^+\)CD103\(^+\) and \(\gamma\delta\)-TCR gene signatures showed a favorable prognostic association with overall survival in HCC.\(^6\) Besides, a high abundance of stem like CD8 T\(_{RM}\) cells CD3\(^+\)CD8\(^+\)CD103\(^+\)CD69\(^+\) has been associated with better patient outcomes in high-grade serous ovarian carcinomas.\(^6\) In melanoma, the increased numbers of CD69\(^+\)CD103\(^+\) CD8+ T\(_{RM}\) cells were associated with improved survival in immunootherapy-naive patients.\(^6\) However, our recent work shows that the abundance of CD8+ T\(_{RM}\) cells CD69\(^+\)CD8\(^+\) T\(_{EM}\) in the BM of AML patients is associated with inferior outcomes (Unpublished data). Coincidentally, Bryant et al found that accumulation of atypical tissue resident CD69\(^+\) terminal effector cells (CD8+CD57+) in myeloma infiltrated BM could prevent differentiation and expansion of clonal myeloma specific CD8+ terminal effector cells and ultimately contribute to myeloma immune escape.\(^6\) These results indicated that the infiltrating of CD69\(^+\) T\(_{RM}\) cell in solid tumors and hematological malignancies may have opposite prognostic values. Mechanisms under these different phenotypes remained to be investigated.
Except to express on tumor infiltrating T\textsubscript{RM} cells, the expression of CD69 on Tregs may also impact the survival of cancer patients. In the tumor tissue of HCC patients, an accumulation of the CD4\textsuperscript{+}CD69\textsuperscript{+} Treg subpopulation has been identified. This particular subpopulation is characterized by the absence of foxp3 or CD25 expression but elevated levels of immune inhibitory molecules, including PD-1 and CTLA-4. The frequency of these cells exhibits a significant correlation with tumor progression, with a more pronounced impact observed in late-stage cancer patients. This observation suggests that this specific CD69\textsuperscript{+} Treg subpopulation may serve as a valuable indicator of adverse prognosis in HCC.\textsuperscript{68} Even there was no other evidence shows that CD69\textsuperscript{+} Treg play an immunosuppression role in other tumor model or human cancer at present, based on its vital role in regulating Treg/Th17 balance and T cell residency, the importance of CD69\textsuperscript{+} Treg in human cancer tissues should be respected.

Except for expression on Treg and T\textsubscript{RM}, which indirectly correlate the cancer prognosis, CD69 has also been found to express on malignant tumor and leukemia cells which have been found with potential value as a prognostic marker. A recent study has unveiled the expression of CD69 within the cells of ovarian clear cell carcinoma. The CD69 expressed in cancer cells facilitated the progression of carcinoma cell through its interaction with fibronectin, consequently contributing to an adverse prognosis for patients.\textsuperscript{69} Another study found a subset of leukemia stem cells with high CD69 expression levels corresponding to self-renewal and enhanced colony-forming capacity, which is responsible for the relapse of acute myeloid leukemia\textsuperscript{70,71} and poor and poor clinical outcomes.\textsuperscript{70} Moreover, CD69 expression was also detected on tumor cells from most other hematological malignancies and was associated with poor clinical outcome. For example, CD69 expression in B-cell non-Hodgkin’s lymphoma is associated with poor treatment response and prognosis, which might be related to increased sensitivity to external stimuli and the risk of DNA damage in the oncogenesis of CD69-positive cells.\textsuperscript{72} CD69 expression on chronic lymphocytic leukemia (CLL) is considered an independent prognostic marker because patients with CD69-positive CLL cells present a weaker response to chemotherapy and shorter overall survival than those with low CD69 expression levels.\textsuperscript{73} In addition, it was reported that CLL cases with high CD69 expression levels in lymph nodes and BM developed higher resistance to bendamustine than to peripheral blood tumor cells.\textsuperscript{74} All the above cancer progression or prognostic relevant studies about CD69 are summarized in Table 1.

### Table 1 CD69 Expression in Predicting Cancer Progression and Prognosis

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>CD69 Expression Cell</th>
<th>Prognostic Relevance</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HNSCC</td>
<td>Unknown, may be CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells</td>
<td>T\textsubscript{RM}-enriched tumors correlated with upregulated inflammatory pathways, upregulation of immunostimulatory and immune checkpoint molecule genes, and favorable OS</td>
<td>[62]</td>
</tr>
<tr>
<td>CRC with liver metastases</td>
<td>Tissue-resident CD69\textsuperscript{+} terminally differentiated V\textdelta1 cells</td>
<td>Increased frequencies of this cell in liver and in peripheral blood significantly correlate with longer OS</td>
<td>[63]</td>
</tr>
<tr>
<td>HCC</td>
<td>V\gamma9V\delta2 T cells</td>
<td>A combined CD69\textsuperscript{+}CD103\textsuperscript{+} and V\delta TCR gene signature showed a favourable prognostic association with OS</td>
<td>[64]</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>CD3\textsuperscript{+}CD8\textsuperscript{+}CD103\textsuperscript{+}CD69\textsuperscript{+}TCF1\textsuperscript{+} stem like TRM cells</td>
<td>Tumor infiltration by CD8\textsuperscript{+} stem like TRM cells strongly associated with superior outcome</td>
<td>[65]</td>
</tr>
<tr>
<td>Melanoma</td>
<td>CD69\textsuperscript{+}, CD103\textsuperscript{+}, PD-1\textsuperscript{+}, LAG-3\textsuperscript{+}, CD8\textsuperscript{+} T cells</td>
<td>Increased numbers of tumor-resident subset are associated with better prognosis.</td>
<td>[66]</td>
</tr>
<tr>
<td>MM</td>
<td>CD69\textsuperscript{+} CD57\textsuperscript{+}CD8\textsuperscript{+} T cells</td>
<td>The accumulation of atypical tissue-resident CD69\textsuperscript{+} terminal effector cells (CD8\textsuperscript{+}CD57\textsuperscript{+}) contributes to immune escape in myeloma</td>
<td>[67]</td>
</tr>
<tr>
<td>HCC</td>
<td>CD25 Foxp3 Treg</td>
<td>The frequency of these cells exhibits a significant correlation with tumor progression, with a more pronounced impact observed in late-stage cancer patients</td>
<td>[68]</td>
</tr>
</tbody>
</table>

(Continued)
Although the underlying mechanism of CD69 in hematological malignancy development remains unclear, the negative prognostic outcome of patients with CD69-expressing tumor cells indicates the potential of CD69 as a therapeutic target, especially against hematological malignancies.

### CD69 Target Therapy in Cancer Treatment

Cumulative evidence suggests that the utilization of anti-CD69 mAb is effective against several autoimmune diseases although CD69 is correlated with the amelioration of some kinds of autoimmune diseases and hypersensitivity. Anti-CD69 mAb effectively ameliorates diseases in animal experiments, including collagen-induced arthritis, airway inflammation, and diarrhea induced by food allergy. GFC-101, an anti-CD69 fully human mAb, is under preclinical study for the treatment of bowel irritable syndrome, rheumatoid arthritis, and respiration disorders.

Targeting CD69 in malignancies is being studied. As early as 2003, a study found that CD69−/− mice challenged with mutant lymphoma cells (RMA-S) and prostate cancer (RM-1) showed reduced tumor growth and metastases and prolonged survival time compared with wild-type mice. Decreased TGF-β production was also observed in CD69−/− mice, and the study verified the upregulation of TGF-β production mediated by CD69.

In 2012, Zhao et al found that upon encountering autologous CD69+ T cells, tumor macrophages acquired the ability to produce large amounts of IDO protein in cancer nests; they proposed that such an active induction of immune tolerance should be considered for the rational design of effective immune-based anticancer therapies.

Recently, Using the CD69-deficient mice, Ryo et al verified that CD69 deficiency attenuates TOX expression in tumor-specific CD8+ T cells in tumor-draining lymph nodes likely through an NFAT-dependent pathway, and thereby promotes the initiation of CD8+ T-cell differentiation, leading to enhanced anti-tumor immune responses. In addition, they also identified that combined treatment with anti-CD69 and anti-PD-1 had an enhanced therapeutic effect on the melanoma mice model when compared with administration anti-CD69 or anti-PD-1 alone.

Other Studies using anti-CD69 antibodies against tumors also supported the possible therapeutic value of targeting CD69 (summarized in Table 2). A study found that the tumor volume of renal cell carcinoma-bearing mice was significantly decreased after injection with a DC-based vaccine and anti-CD69 antibody. This observed phenomenon may be attributed to the upregulation of CD69 expression on T cells following a DC-based vaccine. Subsequent stimulation of T cell activation and proliferation takes place through the cross-linking of CD69 on T cells by anti-CD69. In another study, the application of an anti-CD69 antibody can activate resting NK cells against RMA-S lymphoma and RM-1 prostatic carcinoma lung metastases through increased NK-cell cytolytic activity and IFN-γ production. Besides, in vivo treatment with anti-CD69 also showed a significant reduction in tumor growth and
metastasis, a significant increase in the number of CD4$^+$ and CD8$^+$ TILs, and a reduction in the frequency of profoundly exhausted CD8$^+$ T cells (PD-1$^{hi}$Tim3$^+$), which indirectly suggested the therapeutic effect of anti-CD69. The above studies show that CD69 can act as a target against specific tumors by enhancing the anti-tumor activities of immune cells. Given the potential value of targeting CD69 in cancer immunotherapy, studies on anti-CD69 antibodies against different kinds of tumors in humanized animal models should be launched. While, CD69 is expressed on not only T cells but also almost every leukocyte, side effects from anti-CD69 administration may be unavoidable. Thus, the safety of treatment with a CD69 mAb needs to be further investigated. Evidence from Ryo’s CD69 deficiency mice showed that there was no severe defects occurred, thus they predict that anti-CD69 associated adverse events will be tolerable.

However, strong evidence showed that CD69 plays a role in the balance of Treg/Th17, possible clinical trials targeting the inhibition of CD69 should caution of the risk of inducing autoimmune diseases like asthma, myocarditis, colitis, contact dermatitis, and rheumatoid arthritis and even other side effects. Moreover, the use of mAb itself has a certain risk, which may produce cytokine storm or other adverse reactions. Therefore, more preclinical experiments are needed to verify the safety of CD69 mAb for clinical treatment.

The mechanism of various immune regulatory functions involved in CD69 is inseparable from the relationship between its ligands, so it may be a new therapeutic idea to target the CD69 ligands alone or at the same time for cancer immunotherapy. Gal-1 in particular, is known to be deeply involved in the initiation, amplification, and resolution of inflammatory responses. A growing body of evidence indicates that Gal-1 can suppress the T-cell response through apoptotic and non-apoptotic mechanisms by binding to the glycoproteins (including CD2, CD3, CD7, CD43, CD45 as well as CD69) on T cells. In addition, the expression or overexpression of Gal-1 in various tumors or surrounding tissues is considered to be a sign of malignant tumor progression and, consequently, of a poor prognosis for patients. It has been reported that the blockade of the biological activity of Gal-1 in melanoma tissue results in a reduced tumor mass and stimulates the generation of a tumor-specific T-cell. Taken together, all observations support that Gal-1 may

### Table 2: Researches Based on Anti-CD69 Antibody for Cancer Treatment

<table>
<thead>
<tr>
<th>Cancer Model</th>
<th>Interventions and Combination</th>
<th>Cancer Progression</th>
<th>Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BALB/c mice bearing CT26 CRC; C57BL/6 mice bearing MC38-OVA or B16-OVA Melanoma</td>
<td>Anti-mouse CD69 (H1.2F3) and anti-PD-1, anti-Gal mAbs</td>
<td>Anti-CD69 alone leading to enhanced anti-tumor immune responses. Combined use showed an efficient antitumor effect.</td>
<td>CD69 deficiency attenuates TOX expression in tumor-specific CD8$^+$ T cells in tumor-draining lymph nodes likely through an NFAT-dependent pathway, promoted generation of functional terminally differentiated CD8$^+$ T cells.</td>
<td>[82]</td>
</tr>
<tr>
<td>BALB/c mice bearing RCC</td>
<td>Dendritic cell-based vaccine and anti-CD69 mAb</td>
<td>Combination therapy resulted in significant decrease in tumor volume</td>
<td>Dendritic cell-based vaccine presents tumor antigen to T cells and stimulates T cell activation. Addition of anti-CD69 antibody further induces T-cell activation and proliferation via cross-linking of CD69 on T cells, thereby increasing anticancer efficacy.</td>
<td>[55]</td>
</tr>
<tr>
<td>C57BL/6 mice bearing RMA-S lymphoma, C57BL/6 mice bearing RM-1 PCa lung metastases</td>
<td>Anti-CD69 mAb (H1.2F3)</td>
<td>Application of anti-CD69 mAb drastically reduced tumor metastases</td>
<td>Targeting CD69 results in reduced production of TGF-β and enhanced NK cell antitumor activity.</td>
<td>[83]</td>
</tr>
<tr>
<td>BALB/c bearing 4T1-luc2 breast cancer</td>
<td>Anti-CD69 mAb (H1.2F3)</td>
<td>Anti-CD69 antibody treatment resulted in a significant reduction of tumor growth</td>
<td>Targeting CD69 attenuates CD69-mediated T cell retainment within the tumor, leading to increased numbers of CD4$^+$ and CD8$^+$ T cells and reduction of exhausted T cells.</td>
<td>[53]</td>
</tr>
</tbody>
</table>

**Abbreviations:** CRC, colorectal carcinoma; mAb, monoclonal antibody; NFAT, nuclear factor of activated T cells; RCC, renal cell carcinoma; PCa, prostatic carcinoma; TGF-β, transforming growth factor-β.
contribute to the immune escape of tumors by modulating the survival or polarization of effector T cells. Given the therapeutic benefits associated with Gal-1 blockade, several Gal-1 inhibitors have been designed and evaluated in pre-clinical tumor models.\textsuperscript{88,91} Exception for Gal-1, other ligands of CD69 including Myl9, S100A8, and S100A9 also have been found with the immune microenvironment modulation and tumor promotion ability in different cancers.\textsuperscript{92–95} For example, it has been reported that Myl9 expression is increased in human esophageal squamous cell carcinoma and that Myl9 expression is associated with immune infiltration.\textsuperscript{96,97} Thus, targeting these targets for cancer therapy also should be considered. However, the interaction between CD69 and the above ligands are mostly explored in inflammatory settings, therefore, it is still necessary to further explore how CD69 and its ligands crosstalk in anti-cancer immunotherapy settings in the future studies.

**Conclusion and Prospects**

In earlier studies, CD69 was defined as an activation marker of different leukocyte subsets, especially for T and NK cells, while it was found to be involved in the pathogenesis of several chronic inflammatory diseases. Recent studies have shown that CD69 can regulate the differentiation of Th17/Treg cells toward Treg cells, and the expression of CD69 by T\textsubscript{RM} cells may contribute to their tumor tissue retention and further exhaustion. Besides, anti-CD69 antibody application enhances antitumor effects by activating innate and adaptive T cells, as shown in pre-clinical studies.\textsuperscript{12} These evidences indicate that CD69 may play an immune inhibitory role in antitumor immunity. Thus, CD69 could be considered a target molecule for cancer immunotherapy. However, opposing evidence indicates that CD69 promotes the balance of Th17/Treg cells into Th17 cells, and some patients with CD69\textsuperscript{+} immune cell infiltration within some kinds of tumors (bladder cancer, gastric cancer, lung cancer, and melanoma) also have a positive prognosis.\textsuperscript{38} Therefore, the feasibility of targeting CD69 for cancer immunotherapy should be based on the following points: (i) to establish the correlation between CD69\textsuperscript{+} immune cells and the prognosis in different kinds of tumor; (ii) to ensure the functions of CD69\textsuperscript{+} cells in TMEs, especially for T\textsubscript{RM} cells; (iii) to confirm whether anti-CD69 mAb produces effective cancer suppression effect in humanized animal models; and (iv) to verify the therapeutic value in clinical trials. Further studies will allow people to establish whether targeting CD69 is effective against tumors and produce a possible value of targeting this molecule in clinical cancer treatment.

In addition, CD69 expression on TILs and tumor cells associated with clinical prognosis establishes the independent prognostic value of CD69 in cancer. Studies need to further demonstrate whether CD69 relates to clinical outcomes in different cancers, providing information about the development of specific cancers and CD69 function. Further research into CD69 will shed light on the unique prognostic and therapeutic value of CD69 and its benefits to the clinical treatment of cancer.

**Abbreviation**

BM, bone marrow; CD69, cluster of differentiation 69; CLL, chronic lymphocytic leukemia; CNS, conserved noncoding sequences; DCs, dendritic cells; Gal-1, galactolectin-1; HIF-1α, hypoxia-inducible factor-1α; HCC, hepatocellular carcinoma; KLF2, kruppel-like factor 2; mAb, monoclonal antibody; Myl12, myosin light chain 12; Myl9, myosin light chain 9; Myl9/12, myosin light chain 9, 12a, 12b; NFAT, nuclear factor of activated T cell; NK, natural killer cell; NR4A, nuclear receptor subfamily 4 group A; ox-LDL, oxidized low-density lipoprotein; PD-1, programmed cell death-1; S1P, sphingosine-1-phosphate; S1P1, sphingosine1-phosphate receptor 1; TGF-β, transforming growth factor-β; Th17, T helper cell 17; TILs, tumor-infiltrating T cell; TME, tumor microenvironment; TOX, thymocyte selection associated high mobility group box; Treg, regulatory T cell; TRM, tissue resident memory T cell.

**Acknowledgment**

Yuchen Li and Yinfeng Gu contributed equally to this work and should be considered joint first authors.

**Funding**

This work is supported by grants from the National Natural Science Foundation of China (Nos. 82000108, 82293630, 82293632, 82070152); Guangdong Basic and Applied Basic Research Foundation (2020A1515110310); The Science and
Technology Program of Guangzhou City (No. 202201010164); the Natural Science Foundation of Guangdong Province (No. 2023A1515030271) and the National Innovation and Entrepreneurship Training Program For Undergraduate (No. CX23386).

Disclosure
The authors declare that they have no competing interests.

References


